Myriad Genetics, Inc. · NASDAQ:MYGN
Myriad Genetics — Q4 2025 Earnings Presentation
26 slides from Myriad Genetics's earnings presentation, Feb 23, 2026
Slide 1: Fourth Quarter and Full Year 2025 Earnings Call
Fourth Quarter and Full Year 2025 Earnings Call FEBRUARY 23, 2026 ©2026 Myriad Genetics, Inc.
Slide 2: Forward-looking statements and Non-GAAP financial measures
Forward-looking statements and Non-GAAP financial measures Some of the FORWARD-LOOKING STATEMENTS AND DISCLAIMERS information presented These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these here today contains
Slide 3: Fourth quarter and full year 2025 performance and highlights
Fourth quarter and full year 2025 performance and highlights Entering FY 2026 with positive momentum and a robust pipeline Improved execution across Generated strong Advanced Cancer Care entire organization profitability in Q4 ‘25 Continuum strategy Q4‘25 revenue of $209.8M reflects 70% adj. gross m
Slide 4: Catalysts to watch in 2026E
Catalysts to watch in 2026E HCT Prostate Cancer Precise MRD Prenatal Health • Launch of MyRisk • Launch Prolaris AI Initiate commercial testing for • Report out on FirstGene Disease Specific test; Q2 select customers; (March) CONNECTOR study; H1 Panels; H1 • Prolaris meta-analysis • MolDx submission
Slide 5: Precise MRD: Laying the groundwork for a successful commercial launch
Precise MRD: Laying the groundwork for a successful commercial launch The importance of early commercial testing 1 2 3 Precise MRD (2026E) Opportunity to showcase performance; grow body of Deepen relationships with Tracking early-stage Initiate commercial testing for real-world data community oncolo
Slide 6: Taking actions designed to drive strategic growth
Taking actions designed to drive strategic growth Investing in the Cancer Care Continuum Focus on driving commercial success Expanding of commercial organization Meaningfully increasing field sales team Strengthening Sales Enablement Increasing tools to support product launches, increasing market ac
Slide 7: Business Update
Business Update Mark Verratti CHIEF OPERATIONS OFFICER ©2026 Myriad Genetics, Inc. 7
Slide 8: Continue to drive strong MyRisk test growth; Prolaris momentum
ONCOLOGY Continue to drive strong MyRisk test growth; Prolaris momentum Operational results: Fourth quarter 2025 $84.7M Q4‘25 revenue and recent highlights • MyRisk affected continued to gain market share in Q4 ~56K • Prolaris volume grew 12% YOY in Q4; expect Q4‘25 volume launch of AI-enabled Prola
Slide 9: HCT and Prenatal Health positioned to advance in 2026
W O M E N ’ S H E A LT H HCT and Prenatal Health positioned to advance in 2026 Operational results: Fourth quarter 2025 $88.5M Q4‘25 revenue and recent highlights • 2nd consecutive quarter of double-digit YOY MyRisk unaffected test volume growth ~189K Q4‘25 volume • Prenatal revenue in Q4 was stable
Slide 10: Maintaining leadership with disciplined investment and profit focus
M E N TA L H E A LT H Maintaining leadership with disciplined investment and profit focus Operational results: Fourth quarter 2025 $36.6M and recent highlights Q4‘25 revenue • 38k+ clinicians ordered GeneSight in Q4'25 • Secured positive coverage policies from 12 payers for GeneSight in 2025 ~138K Q
Slide 11: Financial Update
Financial Update Ben Wheeler CHIEF FINANCIAL OFFICER ©2026 Myriad Genetics, Inc. 11
Slide 12: Growth drivers in Q4'25 and FY 2025
Growth drivers in Q4’25 and FY 2025 Select test volume and growth rates All figures in thousands, except growth rates Hereditary Cancer Mental Health1 Additional Highlights: As part of HCT, MyRisk test volume grew 12% and 10% YOY in Q4'25 and 2025, 400 600 6% respectively 350 7% 500 300 250 400 200
Slide 13: Fourth quarter 2025 financial performance
Fourth quarter 2025 financial performance Improving test volume growth and discretionary spend management All figures in millions, except per share amounts and percentages Total revenue Adjusted Gross Margin* Adjusted Operating Expense* Adjusted EPS* Lower by Reduced Higher by 0% 190bps 5% $0.01 YOY
Slide 14: Strong gross profit, adjusted EBITDA, and healthy liquidity position
Strong gross profit, adjusted EBITDA, and healthy liquidity position Additional Highlights: Q4‘25 and FY 2025 adj. Adjusted Gross Profit1 Adjusted EBITDA1 Liquidity position2 operating cash flow1 was Generated approximately Generated approximately Access to $17.9M and $22.1M, respectively $579M $39M
Slide 15: Reaffirming 2026 financial guidance; New Q1'26 commentary
Reaffirming 2026 financial guidance; New Q1‘26 commentary All figures in millions, except percentages 2026 FINANCIAL COMMENTS Additional commentary GUIDANCE Reiterate the full year 2026 revenue Q1’26 range. Q1’26 revenue is expected to be between $200 and $203 million, or 2% Q1’26 adjusted EPS is ex
Slide 16: New Myriad is set to deliver profitable accelerated growth
New Myriad is set to deliver profitable accelerated growth 1 2 3 4 5 Prioritizing focus on the Extending commercial Cancer Care Continuum; reach and leveraging Strengthening Robust new product Myriad has a right to win operational strength Leadership team with execution excellence pipeline and strat
Slide 17: Q&A
Q&A ©2026 Myriad Genetics, Inc. 17
Slide 18: Appendix
Appendix ©2026 Myriad Genetics, Inc. 18
Slide 19: Reconciliation of GAAP to Non-GAAP – Adjusted Gross Margin
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Twelve Months Ended December 31, 2025 and 2024 – Adjusted Gross Margin (unaudited data in millions, except percentages) Three months ended Twelve months ended December 31, December 31, 2025 2024 2025 2024 Adjusted Gross Margin G
Slide 20: Reconciliation of GAAP to Non-GAAP – Adjusted Operating Expenses
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Twelve Months Ended December 31, 2025 and 2024 – Adjusted Operating Expenses (unaudited data in millions) Three months ended Twelve months ended December 31, December 31, 2025 2024 2025 2024 Adjusted Operating Expenses Operating
Slide 21: Reconciliation of GAAP to Non-GAAP – Adjusted Operating Expenses (Cont.)
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Twelve Months Ended December 31, 2025 and 2024 – Adjusted Operating Expenses (Cont.) (1) Represents recurring amortization charges resulting from the acquisition of intangible assets. (2) Expense related to goodwill and long-liv
Slide 22: Reconciliation of GAAP to Non-GAAP – Adjusted Net Income
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Twelve Months Ended December 31, 2025 and 2024 – Adjusted Net Income (unaudited data in millions, except per share amounts) Three months ended Twelve months ended December 31, December 31, 2025 2024 2025 2024 Adjusted Net Income
Slide 23: Reconciliation of GAAP to Non-GAAP – Adjusted Net Income (Cont.)
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Twelve Months Ended December 31, 2025 and 2024 – Adjusted Net Income (Cont.) (1) To determine Adjusted Earnings Per Share, or adjusted EPS. (2) Represents recurring amortization charges resulting from the acquisition of intangib
Slide 24: Reconciliation of GAAP to Non-GAAP – Adjusted EBITDA
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Twelve Months Ended December 31, 2025 and 2024 – Adjusted EBITDA (unaudited data in millions) Three months ended Twelve months ended December 31, December 31, 2025 2024 2025 2024 Adjusted EBITDA Net Loss $ (7.9) $ (42.5) $ (365.
Slide 25: Reconciliation of GAAP to Non-GAAP – Adjusted EBITDA (Cont.)
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Twelve Months Ended December 31, 2025 and 2024 – Adjusted EBITDA (Cont.) (1) Represents recurring amortization charges resulting from the acquisition of intangible assets. (2) Depreciation expense excludes depreciation included
Slide 26: Reconciliation of GAAP to Non-GAAP – Adjusted Free Cash Flow
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Twelve Months Ended December 31, 2025 and 2024 – Adjusted Free Cash Flow (unaudited data in millions) Three months ended Twelve months ended December 31, December 31, 2025 2024 2025 2024 Adjusted operating and free cash flow Net